Key Facts & Figures
Roche Group
Results 2011
- Group sales rise 2% (-10% in Swiss francs; +6% in US dollars), excluding Tamiflu; overall Group sales at 42.5 billion Swiss Francs
- Core operating profit increases by 6%, significantly faster than sales
- Net income increases by 26% to 9.5 billion Swiss Francs (+7% in Swiss Francs)
- Core earnings per share rise 11% due to solid operating performance, lower financing costs and a lower tax rate
Unless otherwise stated, all growth rates are calculated using constant exchange rates (average full-year 2010)
Pharmaceuticals
Results 2011
- Pharmaceuticals sales up 1%, excluding Tamiflu, in line with the market
- Including Tamiflu, sales expressed in constant currencies remained stable at a total of 32.8 billion Swiss francs
- Core operating profit in the Pharmaceuticals Division grew 5% at constant exchange rates to 13.4 billion Swiss francs
- Excellent progress in late-stage pipeline: 17 out of 20 trials delivered positive results in 2011
- 24 key drug approvals and 21 major regulatory filings
Unless otherwise stated, all growth rates are calculated using constant exchange rates (average full-year 2010)
Diagnostics
Results 2011
- Diagnostics sales increase 6%, significantly ahead of the market totalling 9.7 billion Swiss francs in 2011
- Core operating profit in the Diagnostics Division increased by 14% at constant exchange rates to 2.2 billion Swiss francs
- 50 diagnostic tests and 13 instruments launched in key markets
Unless otherwise stated, all growth rates are calculated using constant exchange rates (average full-year 2010)
